Developing new drugs to treat hearing disorders and serious diseases of the central nervous system

News & Events


AutifonyLtd @AutifonyLtd
Autifony Therapeutics regains rights to clinical stage Kv3 programme
RT @singular_talent:Barbara Domayne-Hayman joined us on Careers in Discovery to talk startups, careers and more. Barbara's experience…
Autifony announces commencement of a Phase I study of AUT00201, a novel Kv3 modulator for schizophrenia and hearing…
Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image